Breakthrough for bladder cancer patients as tablet treatment rolled out on NHS - Hundreds will benefit after the first ...

UroGen Pharma's potential remains strong despite market volatility, with promising FDA prospects for UGN-102 & a $5B ...

Hundreds of patients are expected to benefit from the recommendation by the National Institute of Health and Care Excellence.

A new, error-corrected method for detecting cancer from blood samples is much more sensitive and accurate than prior methods ...

The oral drug – Johnson & Johnson's Balversa (erdafitinib) – will become an option for adults with metastatic or unresectable ...

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration ...

The drug, recommended by NICE, works by blocking certain proteins to slow down or stop the growth of cancer cells ...

Bavencio as first-line maintenance was associated with long-term efficacy in advanced urothelial carcinoma regardless of ...

The investigational therapy combines mRNA technology with immunotherapy to train the immune system to target cancer cells ...

Erdafitinib, also known as Balversa and made by Johnson & Johnson, is recommended in final draft guidance for adults with metastatic or unresectable FGFR-altered urothelial cancer who have previously ...